Gynecological Trials
Clinical Trials / Swiss-GO Trials Switzerland [EN]
Swiss-GO-10: ENGOT-cx20/NSGO-CTU/TroFuse-020 (MSD)
Official Study Titel:
"A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer."
Indication
Recurrent or Metastatic Cervical Cancer
Study Design
ponsor : MSD
Studiennahme des Sponors : (TroFuse-020/GOG-3101/ENGOT-cx20)
Öffentliches Studienregister:
clinicaltrials.gov/: nCT06459180
ENGOT Leitgruppe: NSGO -CTU
Webseite:: https://nsgo.org/
Rekrutierung
Fortlaufend
Swiss-GO-10:
The Swiss GO Trial Group represents the Swiss participation in the study (Swiss-GO-12). A total of 2 sites ; Berne Inselspital and USB Basel are participating in the study.
For further information please contact the Swiss GO Trial Group at:
Thank you!
Sponsor
MSD
Lead coordinating ENGOT Group
NSGO-CTU
